Stocks and InvestingStocks and Investing
Fri, December 15, 2023
Thu, December 14, 2023
Wed, December 13, 2023

Lawrence Biegelsen Maintained (ABT) at Buy with Increased Target to $121 on, Dec 13th, 2023


Published on 2024-10-28 07:59:05 - WOPRAI, Lawrence Biegelsen
  Print publication without navigation


Lawrence Biegelsen of Wells Fargo, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $116 to $121 on, Dec 13th, 2023.

Lawrence has made no other calls on ABT in the last 4 months.



There are 4 other peers that have a rating on ABT. Out of the 4 peers that are also analyzing ABT, 1 agrees with Lawrence's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lewis of "Morgan Stanley" Maintained at Hold with Decreased Target to $107 on, Thursday, October 19th, 2023


These are the ratings of the 3 analyists that currently disagree with Lawrence


  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $123 on, Monday, December 11th, 2023
  • Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $133 on, Thursday, October 19th, 2023
  • Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $110 on, Thursday, October 19th, 2023